WEIGHT & METABOLIC RESEARCH

LIPO-C

A lipotropic research blend: the classical MIC factors plus L-carnitine and B-vitamin cofactor precursors in one vial.

LIPO-C combines the three classical lipotropic factors—methionine, inositol, and choline—with L-carnitine, dexpanthenol (provitamin B5), and niacinamide (vitamin B3). The components converge on hepatic lipid handling and mitochondrial fatty-acid metabolism, and each component's identity is verified by high-resolution mass spectrometry. Like all blends, the specific combination itself has not been trial-tested.

MIC + L-Carnitine + B VitaminsLipid MetabolismMitochondrial EnergyLipotropic Blend

Why BLP features LIPO-C

Included because it is a long-used lipotropic combination built from components with textbook-level mechanistic characterization—the carnitine shuttle, coenzyme A, NAD+, and the methylation cycle. The blend itself is not trial-tested, so its evidence is capped accordingly, but decades of established use in metabolic research settings place it above purely experimental compounds.

Mechanism

Methionine, inositol, and choline—the classical lipotropic trio—supply methyl groups and phospholipid precursors that support hepatic lipid export (phosphatidylcholine is required for VLDL assembly).

L-carnitine forms the carnitine shuttle, conjugating long-chain fatty acids and carrying them across the inner mitochondrial membrane for β-oxidation.

Dexpanthenol (provitamin B5) and niacinamide (vitamin B3) are direct precursors of coenzyme A and NAD+, the cofactors that execute fatty-acid oxidation and mitochondrial ATP production.

WHAT THE RESEARCH MEASURED

Research findings

Findings describe study outcomes, not expected personal results.

Human research findings

Component-level: choline is an essential nutrient with defined deficiency outcomes including hepatic steatosis; L-carnitine and myo-inositol each carry independent human trial literature in metabolic contexts.
Lipotropic (MIC-type) blends have decades of use in clinical weight-management settings, but this specific combination has not been evaluated in dedicated human trials.
Reported research use targets lipid metabolism and energy support; effects are attributed to component pharmacology rather than blend-level trial data.

Preclinical findings

Each component's pathway is established core biochemistry: the methylation cycle, phosphoinositide signaling, the carnitine shuttle, CoA-dependent acyl transfer, and NAD+-dependent redox reactions.
Combined lipotropic effects are modeled from convergent pharmacology rather than tested as a blend.

Regulatory status

LIPO-C is a research blend of nutrient and nutrient-derived compounds; the combination is not FDA-approved for any indication. Sold and offered strictly for laboratory and research use.

Related research

NAD+MOTS-C Tesamorelin Evidence Framework Research Library